MedPath

The assessment of efficacy and safety of Irreversible Electroporation(IRE) to treat unresectable locally advanced pancreatic cancer

Not Applicable
Conditions
nresectable locally advanced pancreatic cancer
Registration Number
JPRN-UMIN000016423
Lead Sponsor
Tokyo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

1. distant metastasis, 2. CT or MRI contrast agent allergy, 3. Another organs malignancy, 4. Pregnant women or women of childbearing potential not using an acceptable method of contraception, 5. Uncontrolled infection 6. Heart failure, coronary artery disease or arrhythmia in progress, active implantable devices (eg pacemaker) 7 Patient's disability to stop anticoagulant and anti platelet therapy 8. Attending physician determines that inappropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effectiveness of IRE for treatmetn of unresectable locally advanced pancreatic cancer according to local control rate using CT or MRI performed 6 months after treatment
Secondary Outcome Measures
NameTimeMethod
Incidence and kind of adverse events of up to 1 month after treatment
© Copyright 2025. All Rights Reserved by MedPath